Back to People Listing
Faculty

Ralph Corey

Vice Chair for Education and Global Health, School of Medicine
Gary Hock Professor, Global Health
Director, Hubert-Yeargan Center for Global Health
School of Medicine
Medicine: Infectious Diseases

Trent 233
(919) 668-7174
corey001@mc.duke.edu

Visit Website Download CV

Ralph Corey

Summary

My research is based at the Duke Global Health Institute, as well as the Duke Clinical Research Institute. Combining the global networks at DGHI with the clinical research expertise of our group, it has been able to design and conduct both small local studies to worldwide trials.

The focus of my research has included leishmania and malaria as well as gram positive bacterial infections: complicated skin and skin structure infections; postoperative wound infections; community-acquired, hospital-acquired and ventilator-associated pneumonia; prosthetic joint infections; bacteremia; and endocarditis (involving the International Collaboration on Endocarditis centered at Duke). The team of investigators with whom I work has tremendous collegiality and are amazingly productive.

As a result of my longstanding interest in global health and tropical medicine as well as the generosity of the Hubert, Yeargan, and Hock families, we have been able to establish the Hubert-Yeargan Center for Global Health. As part of our focus on developing innovative global health training within graduate medical education we have partnered with the Duke Global Health Institute to create the Global Health Residency/Fellowship (GHRF) Pathway, a global health program engaging trainees from multiple departments in research and service targeting disadvantaged populations. Distinctive features of the GHRF pathway include broad cross-departmental participation, rigorous didactic training through the Master of Science in Global Health program, and nine months of field experience in a resource-poor setting.

To learn more about the Global Health Residency/Fellowship Pathway and other innovative research and training opportunities, visit the Hubert-Yeargan Center website: http://dukeglobalhealth.org/

Recent Publications

260. Bennett-Guerrero E, Berry S, Bergese SD, Fleshner PR, Minkowitz HS, Segura-Vasi AM, Itani KMF, Henderson KW, Rackowski F, Aberle LH, Stryjewski ME, Corey GR, Allenby KS. A randomized, blinded, multicenter trial of gentamicin vancomycin gel (DFA-02) in patients undergoing abdominal surgery. Am J Surg. In press.

Banks, A and Corey GR. Myocarditis and Pericarditis. Infectious Diseases, Elsevier 2016.

259. Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere SL. Assessment of minimum inhibitory concentrations of Telavancin by revised broth microdilution method in phase 3 hospital-acquired pneumonia/ventilator-associated pneumonia clinical trial isolates. Inf Dis Ther. 2016 Dec; 5(4):535-544. PMID 27718118. Published online October 2016. DOI 10.1007/s40121-016-0133-y.

258. Corey GR, Arhin F, Wikler M, Sahm D, Kreiswirth B, Mediavilla J, Good S, Fiset C, Jiang H, Moeck G, Kabler H, Green S, O’Riordan W. Pooled analysis of single dose oritavancin in the treatment of acute bacterial skin and skin structure infections caused by gram-positive pathogens, including a large patient subset with methicillin-resistant staphylococcus aureus. Int J Antimicrob Agents. 2016 Nov;48(5):528-534. PMID: 27665522. Doi: 10.1016/j.ijantimicag.2016.07.019.

257. Tarakji KG, Mittal S, Kennergren C, Corey GR, Poole J, Stromberg K, Lexcen DR, Wilkoff BL. Worldwide randomized antibiotic envelope Infection Prevention Trial (WRAP-IT). Am Heart J 2016; 180:12-21. PMID: 27659878.

256. Bennett-Guerrero E, Minkowitz HS, Segura-Vasi AM, Marcet JE, White JA, Corey GR, Allenby KS. A randomized, double-blind, placebo controlled safety, tolerability, and pharmacokinetic dose escalation study of a gentamicin vancomycin gel in patients undergoing colorectal surgery. Perioper Med (Lond). 2016 Jun 16;5:17. PMID: 27313846. Doi: 10.1186/s13741-016-0043-2.

255. Sivak JA, Vora AN, Navar AM, Schulte PJ, Crowley AL, Kisslo J, Corey GR, Liao L, Wang A, Velazquez EJ, Samad Z. An approach to improve the negative predictive value and clinical utility of transthoracic echocardiography in suspected native valve infective endocarditis. J Am Soc Echocardiogr 2016. Apr;29(4):315-22. Epub 2016 Feb 3. PMID: 26850679. Doi: 10.1016/j.echo.2015.12.009.

254. Berry SM, Petzold EA, Dull P, Thielman NM, Cunningham CK, Corey GR, McClain MT, Hoover DL, Russell J, Griffiss JM, Woods CW. A response adaptive randomization platform trial for efficient evaluation of ebola virus treatments: A model for pandemic response. Clin Trials. 2016 Feb;13(1):22-30. Epub 2016 Jan 14. PMID: 26768569. Doi: 10.1177/1740774515621721.

Kauf TL, McKinnon P, Corey GR, Bedolla J, Riska PF, Sims M, Jauregui-Peredo L, Friedman B, Hoehns JD, Mercier RC, Garcia-Diaz J, Brenneman SK, Ng D, Lodise T. An open-label, pragmatic randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. BMC Infect Dis. 2015 Nov 7;15:503. doi: 10.1186/s12879-015-1261-9. PMID: 26547411.

Lacy MK, Stryjewski ME, Wang W, Hardin TC, Nogid B, Luke DR, Shorr AF, Corey GR, Barriere SL. Telavancin Hospital-Acquired Pneumonia Trials: Impact of Gram-Negative Infections and Inadequate Gram-Negative Coverage on Clinical Efficacy and All-Cause Mortality. Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S87-93. doi: 10.1093/cid/civ536. PMID:26316562.

Pushkin R, Barriere SL, Wang W, Corey GR, Stryjewski ME. Telavancin for acute bacterial skin and skin structure infections (ABSSSI)-A post-hoc analysis of the Phase 3 ATLAS Trials in consideration of the Final (2013) FDA Guidance. Antimicrob Agents Chemother. Oct;59(10):6170-4. doi: 10.1128/AAC.00471-15. Epub 2015 Jul 27. PMID: 26248356.

Thom H, Thompson JC, Scott DA, Halfpenny N, Sulham K, Corey GR. Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis. Curr Med Res Opin. 2015 Jun 29:1-13 [Epub ahead of print] PMID: 26038985.

Messina JA, Fowler VA Jr, Corey GR. Oritavancin for acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2015 May;16(7):1091-8. Doi: 10.1517/14656566.2015.1026256. Epub 2015 Mar 24. PMID: 25803197.

Durkin MJ, Corey GR. New developments in the management of severe skin and deep skin structure infections-focus on tedizolid. Ther Clin Risk Manag. 2015 May 22;11:857-62. Doi: 10.2147/TCRM.S64553. eCollection 2015. Review. PMID: 26045667.

Stryjewski ME, Jones RN, Corey GR. Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA. Diagn Microbiol Inf Dis. 2015 Mar;81(3):183-8. Doi: 10.1016/j.diagmicrobio.2014.11.016. [Epub ahead of print 2014 Dec 2]. PMID: 25583130.

Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL. Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus. Clin Inf Dis. 2015 Mar 1;60(5):787-96. Doi: 10.1093/cid/ciu971. [Epub ahead of print 2014 Dec 3]. PMID: 25472944.

Shorr A, Lodise T, Corey GR, DeAnda C, Fang E, Das A, Prokocimer P. Analysis of the Phase 3 ESTABLISH Trials: Tedizolid Versus Linezolid in Acute Bacterial Skin and Skin Structure Infection. Antimicrob Agents Chemother. 2014 Nov 24. Pii: AAC.03688-14 [Epub ahead of print]. PMID 25421472.

Chirouze C, Alla F, Fowler VG Jr, Sexton DJ, Corey GR, Chu V, Wang A, Erpelding ML, Durante-Mangoni E, Fernández-Hidalgo N, Giannitsioti E, Hannan MM, Lejko-Zupanc T, Miró JM, Muñoz P, Murdoch DR, Tattevin P, Tribouilloy C, Hoen B; on behalf of the ICE Prospective Investigators. Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis - Analysis in the International Collaboration of Endocarditis - Prospective Cohort Study. Clin Infect Dis. 2014 Nov 10. pii: ciu871. [Epub ahead of print] PMID: 25389255.

Stryjewski ME, Corey GR. NOVA score to predict endocarditis in patients with enterococcal bacteremia: sticking to valves or to scores? Clin Infect Dis. 2014 Nov 7. pii: ciu878. [Epub ahead of print] PMID: 25381322.

Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, Manos P, Keech R, Singh R, Heller B, Bubnova N, O'Riordan W for SOLO II Investigators. Single-dose Oritavancin compared to 7-10 days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: the SOLO II Non-inferiority study. Clin Inf Dis. 2014 Oct 6. pii: ciu778. [Epub ahead of print] PMID: 25294250.

Corey GR, Jiang H, Moeck G. Dalbavancin or oritavancin for skin infections. N Engl J Med. 2014 Sep 18;371(12):1162-3. PMID: 25243251.

Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5. PMID: 24909499.

Corey GR, Kollef MH, Shorr AH, Rubinstein E, Stryjewski ME, Hopkins A, Barriere SL. Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival. Antimicrob Agents Chemother. 2014 Jun;58(6):3581. PMID: 24419353.

Corey GR, Kabler H, Mehra P, Gupta S, Overcash J, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O'Riordan W; SOLO I Investigators. Single-dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. N Engl J Med 2014 June 5:370:2180-90. doi: 10.1056/NEJMoa1310422. PMID: 24897083.

Stryjewski ME, Lentnek A, O'Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG Jr, Barriere SL, Kitt MM, Corey GR. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014 May 23;14:289. doi: 10.1186/1471-2334-14-289. PMID: 24884578.

Barrier SL, Stryjewski ME, Corey GR, Genter FD, Rubinstein E. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies. BMC Infect Dis 2014. 14:183. doi: 10.1186/1471-2334-14-183. PMID: 24708675

Torres A, Rubinstein E, Corey G, Stryjewski M, Barriere S. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicob Chemotherapy. Apr;69(4):1119-26.Published online 1/6/14 doi: 10.1093/jac/dkt490. PMID: 24398339.

Stryjewski ME, Corey GR. Methicillin-resistant staphylococcus aureus: an evolving pathogen. Clinical Infectious Diseases. CID 2014:58 (Suppl 1):S10-19. doi: 10.1093/cid/cit613. PMID: 24343827.